Woman's case prompts contraceptive scrutiny

Switzerland's medicines supervisor says it will analyse all birth control pills after a young woman suffered a lung embolism possibly linked to a contraceptive.

This content was published on June 12, 2009 - 10:43

A spokesman for the Swiss Agency for Therapeutics (Swissmedic) told Swiss television late on Thursday that it had collected extensive research on various birth control pills and would come to a finding on their health effects in the autumn.

The announcement comes after a 16-year-old woman suffered a lung embolism that left her severely disabled. She had been taking Yasmin birth-control pills produced by Germany's Bayer company.

Bayer contends the drug presents no more risk for venal thrombosis than other contraceptive pills.

"We assume that Swissmedic's analysis concerning Yasmin will yield no new findings because Yasmin is one of the most well researched birth-control pills worldwide," the company said. with agencies

This article was automatically imported from our old content management system. If you see any display errors, please let us know:

Share this story

Join the conversation!

With a SWI account, you have the opportunity to contribute on our website.

You can Login or register here.